Differential antiviral and anti-inflammatory mechanisms of the flavonoids biochanin A and baicalein in H5N1 influenza A virus-infected cells

Antiviral Research

Volumn 97, Issue 1, 2013, Pages 41-48

  Sithisarn, Patchima ^a   Michaelis, Martin ^a,b   Schubert Zsilavecz, Manfred ^a   Cinatl, Jindrich ^a  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY OF KENT   (United Kingdom)

Author keywords

Anti inflammatory; Antiviral; Baicalein; Biochanin A; Flavonoid; H5N1

Indexed keywords

APIGENIN; BAICALEIN; BIOCHANIN A; CASPASE 3; FLAVONOID; GAMMA INTERFERON INDUCIBLE PROTEIN 10; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; INTERLEUKIN 8; KAEMPFEROL; LUTEOLIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NARINGENIN; NUCLEOPROTEIN; PROTEIN KINASE B; RIBAVIRIN; RIBONUCLEOPROTEIN; VIRUS SIALIDASE; ZANAMIVIR;

ADSORPTION; ANTIINFLAMMATORY ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG INHIBITION; DRUG SELECTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IC 50; INFLUENZA VIRUS A H5N1; LUNG ALVEOLUS EPITHELIUM; MACROPHAGE; MONOCYTE; MONOCYTE DERIVED MACROPHAGE; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; VIRUS REPLICATION; VIRUS STRAIN;

ANTI-INFLAMMATORY AGENTS; ANTIVIRAL AGENTS; CELLS, CULTURED; CYTOKINES; DRUG EVALUATION, PRECLINICAL; DRUG SYNERGISM; EPITHELIAL CELLS; FLAVANONES; FLAVONOIDS; GENISTEIN; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INHIBITORY CONCENTRATION 50; MACROPHAGES; MICROBIAL SENSITIVITY TESTS; SIGNAL TRANSDUCTION; VIRAL LOAD; VIRUS REPLICATION; ZANAMIVIR;

AVES; INFLUENZA A VIRUS;

EID: 84870325135     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2012.10.004     Document Type: Article

References (51)

1. Bavagnoli L., Maga G. The 2009 influenza pandemic: promising lessons for antiviral therapy for future outbreaks. Curr. Med. Chem. 2011, 18:5466-5475.
2. Biswas S.K., McClure D., Jimenez L.A., Megson I.L., Rahman I. Curcumin induces glutathione biosynthesis and inhibits NF-kappaB activation and interleukin-8 release in alveolar epithelial cells: mechanism of free radical scavenging activity. Antioxid. Redox. Signal. 2005, 7:32-41.
3. Cavet M.E., Harrington K.L., Vollmer T.R., Ward K.W., Zhang J.Z. Anti-inflammatory and anti-oxidative effects of the green tea polyphenol epigallocatechin gallate in human corneal epithelial cells. Mol. Vis. 2011, 17:533-542.
4. Chan M.C., Cheung C.Y., Chui W.H., Tsao S.W., Nicholls J.M., Chan Y.O., Chan R.W., Long H.T., Poon L.L., Guan Y., Peiris J.S. Proinflammatory cytokine responses induced by influenza A (H5N1) viruses in primary human alveolar and bronchial epithelial cells. Respir. Res. 2005, 6:135.
5. Chen L., Dou J., Su Z., Zhou H., Wang H., Zhou W., Guo Q., Zhou C. Synergistic activity of baicalein with ribavirin against influenza A (H1N1) virus infections in cell culture and in mice. Antiviral Res. 2011, 91:314-320.
6. Cheung C.Y., Poon L.L., Lau A.S., Luk W., Lau Y.L., Shortridge K.F., Gordon S., Guan Y., Peiris J.S. Induction of proinflammatory cytokines in human macrophages by influenza A (H5N1) viruses: a mechanism for the unusual severity of human disease?. Lancet 2002, 360:1831-1837.
7. Cheung C.L., Rayner J.M., Smith G.J., Wang P., Naipospos T.S., Zhang J., Yuen K.Y., Webster R.G., Peiris J.S., Guan Y., Chen H. Distribution of amantadine-resistant H5N1 avian influenza variants in Asia. J. Infect. Dis. 2006, 193:1626-1629.
8. Cinatl J., Michaelis M., Doerr H.W. The threat of avian influenza A (H5N1). Part III: antiviral therapy. Med. Microbiol. Immunol. 2007, 196:203-212.
9. Cinatl J., Michaelis M., Doerr H.W. The threat of avian influenza A (H5N1). Part IV: development of vaccines. Med. Microbiol. Immunol. 2007, 196:213-225.
10. de Jong M.D. H5N1 transmission and disease: observations from the frontlines. Pediatr. Infect. Dis. J. 2008, 27:S54-S56.
11. de Jong M.D., Simmons C.P., Thanh T.T., Hien V.M., Smith G.J., Chau T.N., Hoang D.M., Chau N.V., Khanh T.H., Dong V.C., Qui P.T., Cam B.V., Ha D.Q., Guan Y., Peiris J.S., Chinh N.T., Hien T.T., Farrar J. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat. Med. 2006, 12:1203-1207.
12. Deng R., Lu M., Korteweg C., Gao Z., McNutt M.A., Ye J., Zhang T., Gu J. Distinctly different expression of cytokines and chemokines in the lungs of two H5N1 avian influenza patients. J. Pathol. 2008, 216:328-336.
13. Deyde V.M., Xu X., Bright R.A., Shaw M., Smith C.B., Zhang Y., Shu Y., Gubareva L.V., Cox N.J., Klimov A.I. Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide. J. Infect. Dis. 2007, 196:249-257.
14. Geiler J., Michaelis M., Naczk P., Leutz A., Langer K., Doerr H.W., Cinatl J. N-acetyl-l-cysteine (NAC) inhibits virus replication and expression of pro-inflammatory molecules in A549 cells infected with highly pathogenic H5N1 influenza A virus. Biochem. Pharmacol. 2010, 79:413-420.
15. Geiler J., Michaelis M., Sithisarn P., Cinatl J. Comparison of pro-inflammatory cytokine expression and cellular signal transduction in human macrophages infected with different influenza A viruses. Med. Microbiol. Immunol. 2011, 200:53-60.
16. Grienke U., Schmidtke M., von Grafenstein S., Kirchmair J., Liedl K.R., Rollinger J.M. Influenza neuraminidase: a druggable target for natural products. Nat. Prod. Rep. 2012, 29:11-36.
17. Guan Y., Poon L.L., Cheung C.Y., Ellis T.M., Lim W., Lipatov A.S., Chan K.H., Sturm-Ramirez K.M., Cheung C.L., Leung Y.H., Yuen K.Y., Webster R.G., Peiris J.S. H5N1 influenza: a protean pandemic threat. Proc. Natl. Acad. Sci. USA 2004, 101:8156-8161.
18. Hampson A.W. Vaccines for pandemic influenza. The history of our current vaccines, their limitations and the requirements to deal with a pandemic threat. Ann. Acad. Med. Singapore 2008, 37:510-517.
19. Harborne J.B., Williams C.A. Advances in flavonoid research since 1992. Phytochemistry 2000, 55:481-504.
20. Hatta Y., Hershberger K., Shinya K., Proll S.C., Dubielzig R.R., Hatta M., Katze M.G., Kawaoka Y., Suresh M. Viral replication rate regulates clinical outcome and CD8 T cell responses during highly pathogenic H5N1 influenza virus infection in mice. PLoS Pathog. 2010, 6:e1001139.
21. Hayashi S., Jibiki I., Asai Y., Gon Y., Kobayashi T., Ichiwata T., Shimizu K., Hashimoto S. Analysis of gene expression in human bronchial epithelial cells upon influenza virus infection and regulation by p38 mitogen-activated protein kinase and c-Jun-N-terminal kinase. Respirology 2008, 13:203-214.
22. Hecht S.S., Huang C., Stoner G.D., Li J., Kenney P.M., Sturla S.J., Carmella S.G. Identification of cyanidin glycosides as constituents of freeze-dried black raspberries which inhibit anti-benzo[a]pyrene-7,8-diol-9,10-epoxide induced NFkappaB and AP-1 activity. Carcinogenesis 2006, 27:1617-1626.
23. Hien N.D., Ha N.H., Van N.T., Ha N.T., Lien T.T., Thai N.Q., Trang V.D., Shimbo T., Takahashi Y., Kato Y., Kawana A., Akita S., Kudo K. Human infection with highly pathogenic avian influenza virus (H5N1) in northern Vietnam, 2004-2005. Emerg. Infect. Dis. 2009, 15:19-23.
24. Kieny M.P., Fukuda K. The pandemic influenza vaccine challenge. Vaccine 2008, 26(Suppl. 4):D3-D4.
25. Kim Y., Narayanan S., Chang K.O. Inhibition of influenza virus replication by plant-derived isoquercetin. Antiviral Res. 2010, 88:227-235.
26. Kole L., Giri B., Manna S.K., Pal B., Ghosh S. Biochanin-A, an isoflavon, showed anti-proliferative and anti-inflammatory activities through the inhibition of iNOS expression, p38-MAPK and ATF-2 phosphorylation and blocking NFkappaB nuclear translocation. Eur. J. Pharmacol. 2011, 653:8-15.
27. Lee N., Wong C.K., Chan P.K., Lun S.W., Lui G., Wong B., Hui D.S., Lam C.-W., Cockram C.S., Choi K.W., Yeung A.C., Tang J.W., Sung J.J. Hypercytokinemia and hyperactivation of phosphor-p38 mitogen activated protein kinase in severe human influenza A virus infection. Clin. Infect. Dis. 2007, 45:723-731.
28. Lee S.M., Gai W.W., Cheung T.K., Peiris J.S. Antiviral effect of a selective COX-2 inhibitor on H5N1 infection in vitro. Antiviral Res. 2011, 91:330-334.
29. Li C., Bankhead A., Eisfeld A.J., Hatta Y., Jeng S., Chang J.H., Aicher L.D., Proll S., Ellis A.L., Law G.L., Waters K.M., Neumann G., Katze M.G., McWeeney S., Kawaoka Y. Host regulatory network response to infection with highly pathogenic H5N1 avian influenza virus. J. Virol. 2011, 85:10955-10967.
30. Liu A.L., Wang H.D., Lee S.M., Wang Y.T., Du G.H. Structure-activity relationship of flavonoids as influenza virus neuraminidase inhibitors and their in vitro antiviral activities. Bioorg. Med. Chem. 2008, 16:7141-7147.
31. Ludwig S. Disruption of virus-host cell interactions and cell signaling pathways as an -viral approach against influenza virus infections. Biol. Chem. 2011, 392:837-847.
32. Maines T.R., Szretter K.J., Perrone L., Belser J.A., Bright R.A., Zeng H., Tumpey T.M., Katz J.M. Pathogenesis of emerging avian influenza viruses in mammals and the host innate immune response. Immunol. Rev. 2008, 225:68-84.
33. McKimm-Breschkin J.L., Selleck P.W., Usman T.B., Johnson M.A. Reduced sensitivity of influenza A (H5N1) to oseltamivir. Emerg. Infect. Dis. 2007, 13:1354-1357.
34. Michaelis M., Doerr H.W., Cinatl J. Of chickens and men: avian influenza in humans. Curr. Mol. Med. 2009, 9:131-151.
35. Michaelis M., Geiler J., Naczk P., Sithisarn P., Leutz A., Doerr H.W., Cinatl J. Glycyrrhizin exerts antioxidative effects in H5N1 influenza A virus-infected cells and inhibits virus replication and pro-inflammatory gene expression. PLoS ONE 2011, 6:e19705.
36. Moscona A. Global transmission of oseltamivir-resistant influenza. N. Engl. J. Med. 2009, 360:953-956.
37. Nijveldt R.J., van Nood E., van Hoorn D.E., Boelens P.G., van Norren K., van Leeuwen P.A. Flavonoids: a review of probable mechanisms of action and potential applications. Am. J. Clin. Nutr. 2001, 74:418-425.
38. Pinto R., Herold S., Cakarova L., Hoegner K., Lohmeyer J., Planz O., Pleschka S. Inhibition of influenza virus-induced NF-kappaB and Raf/MEK/ERK activation can reduce both virus titers and cytokine expression simultaneously in vitro and in vivo. Antiviral Res. 2011, 92:45-56.
39. Reed L.I., Muench H. A simple method of estimating fifty per cent endpoints. Am. J. Hyg. 1938, 27:493-497.
40. Salter A., Ni L.B., Crowley B. Emergence and phylogenetic analysis of amantadine-resistant influenza a subtype H3N2 viruses in Dublin, Ireland, over Six Seasons from 2003/2004 to 2008/2009. Intervirology 2011, 54:305-315.
41. Sen P., Chakraborty P.K., Raha S. Tea polyphenol epigallocatechin 3-gallate impedes the anti-apoptotic effects of low-grade repetitive stress through inhibition of Akt and NFkappaB survival pathways. FEBS Lett. 2006, 580:278-284.
42. Shin Y.K., Liu Q., Tikoo S.K., Babiuk L.A., Zhou Y. Effect of the phosphatidylinositol 3-kinase/Akt pathway on influenza A virus propagation. J. Gen. Virol. 2007, 88:942-950.
43. Song J.M., Park K.D., Lee K.H., Byun Y.H., Park J.H., Kim S.H., Kim J.H., Seong B.L. Biological evaluation of anti-influenza viral activity of semi-synthetic catechin derivatives. Antiviral Res. 2007, 76:178-185.
44. Sugrue R.J., Tan B.H., Yeo D.S., Sutejo R. Antiviral drugs for the control of pandemic influenza virus. Ann. Acad. Med. Singapore 2008, 37:518-524.
45. van der Vries E., van den Berg B., Schutten M. Fatal oseltamivir-resistant influenza virus infection. N. Engl. J. Med. 2008, 359:1074-1076.
46. van Riel D., Munster V.J., de Wit E., Rimmelzwaan G.F., Fouchier R.A., Osterhaus A.D., Kuiken T. H5N1 virus attachment to lower respiratory tract. Science 2006, 312:399.
47. Wang X., Jia W., Zhao A., Wang X. Anti-influenza agents from plants and traditional Chinese medicine. Phytother Res 2006, 20:335-341.
48. Woo P.C., Tung E.T., Chan K.H., Lau C.C., Lau S.K., Yuen K.Y. Cytokine profiles induced by the novel swine-origin influenza A/H1N1 virus: implications for treatment strategies. J. Infect. Dis. 2010, 201:346-353.
49. Wurzer W.J., Planz O., Ehrhardt C., Giner M., Silberzahn T., Pleschka S., Ludwig S. Caspase 3 activation is essential for efficient influenza virus propagation. EMBO J. 2003, 22:2717-2728.
50. Xu G., Dou J., Zhang L., Guo Q., Zhou C. Inhibitory effects of baicalein on the influenza virus in vivo is determined by baicalin in the serum. Biol. Pharm. Bull. 2010, 33:238-243.
51. Zheng B.J., Chan K.W., Lin Y.P., Zhao G.Y., Chan C., Zhang H.J., Chen H.L., Wong S.S., Lau S.K., Woo P.C., Chan K.H., Jin D.Y., Yuen K.Y. Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1 virus. Proc. Natl. Acad. Sci. USA 2008, 105:8091-8096.